Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...
Three experts explain how obstructive sleep apnea, an often-ignored cardiovascular risk factor, may affect your heart and treatment options.
Dr. David Blaine and Dr. Justin Douglas, otolaryngologists at the Beckley ARH Hospital Ear, Nose and Throat Clinic, recently ...
IHL-42X is designed to treat OSA by targeting its underlying pathophysiology. An oral fixed-dose combination of dronabinol and acetazolamide, IHL-42X is currently advancing through the RePOSA Phase ...
Sleep apnea can have untold consequences even in your waking hours. The good news? The condition is treatable.
We recently published a list of Jim Cramer is Discussing These 10 Stocks Ahead of Q1 Earnings Season. In this article, we are ...
The prevalence of metabolic dysfunction–associated steatotic liver disease, chronic kidney disease, and obstructive sleep ...
Sleep disorders are common, yet many individuals suffering from conditions like sleep apnea remain unaware of their condition ...
A series of sleep studies confirmed that Guber had severe obstructive sleep apnea and was ceasing to breathe for several ...
Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback